| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 6,136 | 24,091 | ||
| General and administrative | 2,809 | 3,201 | ||
| Total operating expenses | 8,945 | 27,292 | ||
| Loss from operations | -8,945 | -27,292 | ||
| Other income, net | 321 | 484 | ||
| Net loss | -8,624 | -26,808 | ||
| Unrealized gain on marketable securities | 24 | -7 | ||
| Total comprehensive loss | -8,600 | -26,815 | ||
| Earnings per share, basic | -3.22 | -11.29 | ||
| Earnings per share, diluted | -3.22 | -11.29 | ||
| Weighted average number of shares outstanding, basic | 2,676,116 | 2,374,729 | ||
| Weighted average number of shares outstanding, diluted | 2,676,116 | 2,374,729 | ||
NextCure, Inc. (NXTC)
NextCure, Inc. (NXTC)